within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX07_Enfuvirtide;

model Enfuvirtide
  extends Pharmacolibrary.Drugs.ATC.J.J05AX07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AX07</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Enfuvirtide is a synthetic 36-amino acid peptide and a fusion inhibitor antiretroviral drug used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is approved for use in combination with other antiretrovirals for patients experiencing treatment failure or resistance. Enfuvirtide is administered by subcutaneous injection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in HIV-1 infected adult patients after subcutaneous injection. Data based on steady state following twice daily 90 mg dosing.</p><h4>References</h4><ol><li><p>Zhang, X, et al., &amp; Patel, IH (2002). Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. <i>Clinical pharmacology and therapeutics</i> 72(1) 10–19. DOI:<a href=\"https://doi.org/10.1067/mcp.2002.125945\">10.1067/mcp.2002.125945</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12152000/\">https://pubmed.ncbi.nlm.nih.gov/12152000</a></p></li><li><p>Chen, RY, et al., &amp; Saag, MS (2002). Enfuvirtide. <i>Expert opinion on investigational drugs</i> 11(12) 1837–1843. DOI:<a href=\"https://doi.org/10.1517/13543784.11.12.1837\">10.1517/13543784.11.12.1837</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12457443/\">https://pubmed.ncbi.nlm.nih.gov/12457443</a></p></li><li><p>Lalezari, JP, et al., &amp; Kinchelow, T (2003). Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. <i>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</i> 28(2) 217–222. DOI:<a href=\"https://doi.org/10.1016/s1386-6532(03)00116-1\">10.1016/s1386-6532(03)00116-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12957192/\">https://pubmed.ncbi.nlm.nih.gov/12957192</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Enfuvirtide;
